NRx Pharma's NRX100: FDA Push for Safer Ketamine Amidst Market Shortage

NRX Pharmaceuticals' FDA Filing for NRX100

• 💡 NRX Pharmaceuticals has filed an abbreviated new drug application with the FDA for NRX100, an innovative preservative-free IV ketamine formulation.
• 🎯 This filing addresses the growing US shortage of ketamine, a market projected to reach $6.1 billion globally by 2033.

Eliminating Neurotoxic Preservatives

• 🔬 NRX100 eliminates benzothonium chloride, identified as a neurotoxic preservative.
• ✅ This move aligns with federal efforts to remove harmful additives from drugs and foods.
• ⚠️ The company also plans to file a citizens petition urging the FDA to ban this preservative in all IV ketamine products.

Regulatory Pathway and Market Potential

• 🚀 NRX anticipates priority review for NRX100 due to the existing ketamine shortage.
• 📈 This filing complements their ongoing new drug application for treating suicidal depression, supported by data from over 180,000 patients.
• 🔑 With FastTrack designation and patent protection through 2045, NRX100 aims to redefine standards for safer ketamine therapies.